KALY - Kali, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0131
-0.0006 (-4.38%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.0137
Open0.0135
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0131 - 0.0140
52 Week Range0.0002 - 0.0393
Volume11,650,173
Avg. Volume19,103,248
Market Cap15.933M
Beta (3Y Monthly)-63.18
PE Ratio (TTM)0.00
EPS (TTM)7.9550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • KALY Announces Hemp4mula CBD Gum NOW Available On USMJ.com
    GlobeNewswireyesterday

    KALY Announces Hemp4mula CBD Gum NOW Available On USMJ.com

    Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) announced today that its Hemp4mula CBD gum is now available for sale on line at USMJ.com.  KALY acquired a patented cannabis extraction process in the fourth quarter of 2019 and has rapidly implemented a multitiered strategy to monetize the value of the patented process.  The company has recently announced a $300,000 order of its proprietary extract and revealed four years of research and development targeting $170 billion worth of pharmaceutical treatments. The announcement today is a further indication of KALY’s progress toward a $1 million revenue target for 2018 in addition to potentially building billions in asset value from its ongoing cannabis extract pharmaceutical research and development.

  • GlobeNewswire6 days ago

    KALY Targets First $1 Million In Cannabis Extract Sales For Consumer Market

    DALLAS, April 17, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a presentation elaborating on the company’s overall strategy to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.  In addition to detailing its cannabis extracts biopharmaceutical strategy, the presentation includes details on KALY’s parallel consumer market strategy separate from the pharmaceutical industry.  Management is targeting $1 million in sales outside the pharmaceutical space in 2019.  See the full presentation published today below.

  • GlobeNewswire6 days ago

    Kali Extracts Presents Cannabis Extract Biopharmaceutical Strategy Targeting $170 Million Pharmaceutical Market Opportunity

    DALLAS, April 17, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a presentation elaborating on the company’s overall strategy to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.  KALY owns and operates a patented cannabis extraction process.

  • GlobeNewswire7 days ago

    PURA Record 2018 Cannabis Beverages Sales Growth Gets Boost From KALY Partnership In 2019

    DALLAS, April 16, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (PURA) (“PURA”) today reported over 350% year to year growth between 2017 and 2018.  The Company filed its annual financial statement reporting over $1.2 million in revenue for year-end December 31, 2018 with over $500,000 in net profit.  Management attributes the more than 350% revenue growth to the success of the company’s EVERx CBD Sports Beverage. With the company’s recently reported enhanced partnership with Kali-Extracts, (KALY) (“KALY”), management expects cannabis beverage diversification and continued rapid growth in 2019.  On Friday, this week, April 19th, 2019, PURA management will publish an online shareholder report with more details and insight on the company’s 2018 growth and ongoing anticipated growth in 2019.  The online report is expected to include updates on PURA’s work with KALY to produce new beverages.

  • GlobeNewswire7 days ago

    PURA - Puration Reports $1.2 Million In Revenue With $500,000 Net Profit In 2018 Year-End Financial Report

    DALLAS, April 16, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (PURA) (“PURA”) today announced filing the company’s annual financial statement reporting over $1.2 million in revenue for year-end December 31, 2018 with over $500,000 in net profit.  Management attributes the more than 350% revenue growth in 2018 from the less than $300,000 in revenue reported in 2017 to the success of the company’s EVERx CBD Sports Beverage. With the company’s recently reported enhanced partnership with Kali-Extracts, (KALY) (“KALY”), management expects cannabis beverage diversification and continued rapid growth in 2019.  PURA is working closely with the company’s co-packer/partner Alkame Holdings, (ALKM) to expand production capacity and keep up with PURA’s growing sales.  PURA is also working with North American Cannabis Holdings, (aka USMJ) (USMJ) to update PURA’s distribution channels to keep up with USMJ’s online retail sales at USMJ.com and simultaneously meet wholesale demand.

  • GlobeNewswire8 days ago

    KALY – Kali Extracts Announces Patented Cannabis Extracts Targeting $170 Million In Pharmaceutical Treatments

    DALLAS, April 15, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) has recently announced ongoing cannabis extract.

  • GlobeNewswire12 days ago

    Kali-Extracts Hemp4mula CBD Infused Gum For Sale On USMJ.com Next Week

    DALLAS, April 11, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) is a health and wellness company set to generate.

  • GlobeNewswire14 days ago

    Kali-Extracts To Present Cannabis Treatment R&D For $170 Million In Pharmaceutical Market Opportunity On April 17th

    DALLAS, April 09, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online presentation scheduled.

  • GlobeNewswire14 days ago

    Kali-Extracts Announces Cannabis Treatment For $9 Billion Epilepsy Market Under Development

    DALLAS, April 09, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced a treatment for epilepsy derived.

  • GlobeNewswire18 days ago

    Kali-Extracts Confirms 4th Cannabis Extract Pharmaceutical Research Project Adding To Research Targeting $160 Million Market

    DALLAS, April 05, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed plans to reveal a fourth research.

  • GlobeNewswire19 days ago

    Kali-Extracts Announces Developing Cannabis Pain Management Treatment For $83 Billion Market Specifically Targeting Cancer

    DALLAS, April 04, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today announced its ongoing research and development of a cannabis pain management treatment derived from the company’s patented cannabis extraction process.  While cannabis for pain management treatment from cancer is not new, KALY is developing a proprietary extract that improves upon the cannabis treatments currently approved by the FDA.  The FDA approved a marijuana treatment for aiding in the management of cancer symptoms and the side effects of other cancer treatments in 1985.

  • GlobeNewswire21 days ago

    KALY - Kali-Extracts Develops Cannabis Treatment For Type 2 Diabetes Expected To Be $64 Billion Market

    DALLAS, April 02, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today unveiled its ongoing research and development.

  • KALY - Kali-Extracts Announces 25 mg CBD Extract Formulation For $600 Million Cannabis Beverage Market
    GlobeNewswire25 days ago

    KALY - Kali-Extracts Announces 25 mg CBD Extract Formulation For $600 Million Cannabis Beverage Market

    DALLAS, March 29, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today announced finalizing it’s all new 25 mg CBD Extract formulation for beverage infusion.  KALY’s patented extraction process already produces a 10 mg CBD formulation for Puration, Inc.’s (PURA) (“PURA”) leading EVERx CBD Sports Water.  Few CBD beverages today even have 5 mg of CBD and now KALY will supply a 25 mg formulation.  Management thoroughly evaluated the 25 mg CBD formulation for infusion into a drink that is clear looking and tasting in a suspension with an effective retail shelf-life.  KALY indicates its formulation will be on shelves infused into its first beverage within the next 30 days. KALY earlier this week announced that the State of Texas plans to remove hemp as a controlled substance next week in conjunction with the United States 2018 Farm Act is just the type of market condition management is looking for to support the implantation of the previously announced cannabis extraction lab to be dedicated to the 100 acre hemp farm to be operated by partner Nouveau (NOUV).  KALY and NOUV plan to partner on the development of a proprietary hemp cultivar dedicated to the advancement of KALY’s pharmaceutical extract developments.  The continuing liberalization of cannabis laws, such as the hemp removal as a controlled substance in Texas, supports the work KALY is advancing.

  • GlobeNewswire28 days ago

    KALY Announces A New Step Forward For Its Cannabis Extraction Lab

    DALLAS, March 26, 2019 -- via OTC PR WIRE --  Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced that the State of Texas plans to.

  • GlobeNewswirelast month

    USMJ and PURA Update Dividend Distribution Plans With PJET and NOUV To Include New Developments With WCVC and KALY

    DALLAS, March 22, 2019 -- via OTC PR WIRE -- North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) and Puration Inc. (USOTC: PURA) (“PURA”) today published an update on.

  • PR Newswirelast month

    KALY Publishes Cannabis Extract COPD Treatment Study Report

    DALLAS , March 22, 2019 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today published the research report on the recent pilot treatment of Chronic ...

  • GlobeNewswirelast month

    KALY Confirms Pharmaceutical Cannabis Extract Report On Recent Trials Scheduled For Tomorrow

    DALLAS, March 21, 2019 -- -- via OTC PR WIRE --  Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the company plans to publish.

  • GlobeNewswirelast month

    KALY Phase One Cannabis Extract COPD Research To Be Published This Friday, March 22, 2019

    DALLAS, March 20, 2019 -- via OTC PR WIRE --   Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company plans to publish its.

  • GlobeNewswirelast month

    KALY Initiates Phase Two Cannabis Extract COPD Treatment Study

    DALLAS, March 18, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced Professor Jeffry Osbourn, Ph.D.,.

  • GlobeNewswire2 months ago

    KALY Cannabis Patent Featured In PURA Report On Progress Toward $5 Million Sales Goal

    DALLAS, March 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today announced the company’s recent advances developing a CBD extract for infusion into a beverage at a 25 mg concentration were featured in a report published yesterday by Puration, Inc. (PURA) (“PURA”).  PURA yesterday reported recent progress toward the company’s $5 million 2019 sales goal.  The report included an overview of KALY’s role using its patented extraction process to develop a CBD extract that will sustain suspension in a beverage at a consistent concentrate level of 25 mg.  The first target beverage for the 25 mg CBD concentrate beverage is a private labeled health water for Generex Biotechnology (GNBT).

  • Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
    GlobeNewswire2 months ago

    Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest

    DALLAS, March 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (PURA) today published a presentation, to review new orders, opportunities and partnerships stemming from the EVERx CBD Sports Water event this past weekend at the Arnold Sports Festival.

  • PURA EVERx Arnold Wrap Presentation to Include KALY Updates
    PR Newswire2 months ago

    PURA EVERx Arnold Wrap Presentation to Include KALY Updates

    DALLAS , March 5, 2019 /PRNewswire/ -- Puration, Inc. (USOTC: PURA) has scheduled an online presentation, this Thursday, March 7 th , 2019 to review new orders, opportunities and partnerships stemming ...

  • GlobeNewswire2 months ago

    PURA - Puration Announces Analyst Update Report Coming Thursday February 28, 2019

    DALLAS, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Puration, Inc. (PURA) today announced an upcoming analyst update report expected to be published this Thursday, February 28, 2019.  The report expected on Thursday will be a second update from Goldman Small Cap Research which initiated analyst coverage in October last year and published a first update in November of last year confirming a Speculative Buy and $0.25 Target PPS.  The company has since the first update signed additional contracts and launched an all new formulation and packaging of its EVERx CBD Sports Water.  Earlier today, the company previewed a major coming announcement regarding its EVERx CBD Sports Water planned for release later this week. The previewed announcement expected later this week is separate from the Analyst Report update planned for release on Thursday this week.  The update report is anticipated to include an assessment of PURA’s $1.5 million contract with Generex Biotechnology (GNBT) to produce custom, private ladled, CBD Infused water for Generex.  PURA is working with Kali-Extracts (KALY) to develop the customer CBD extract formulation for infusion into the water produced for Generex.

  • GlobeNewswire2 months ago

    KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study

    DALLAS, Feb. 21, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process.  The first preview was published on February 5, 2019.  The full report is expected within the next 2 weeks. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

  • GlobeNewswire2 months ago

    USMJ Announces 8% Growth From Core Operations Before Contributions From New eCommerce Business

    DALLAS, Feb. 20, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  North American Cannabis Holdings, Inc. (USMJ)  (“USMJ”) today announced publishing its quarterly financial report for the period ending December 31, 2018.  The company reported $233,000 in revenue for the quarter with a net profit of $18,500.  Revenue is approximately 8% higher than reported for the same period in the prior year.  USMJ recently launched its all new eCommerce site for CBD products and other cannabis essentials at WWW.USMJ.COM. Management anticipates the new eCommerce site to produce the majority of the company’s revenue and growth moving forward.  The current financial report does not include any benefit yet from the new eCommerce site.  USMJ plans to continue expanding the number and variety of products available from WWW.USMJ.COM.  The site includes EVERx CBD Sports Water from USMJ’s sister company, Puration Inc. (PURA).